查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840899

肌萎縮側索硬化症治療市場（按治療方法、類型、治療階段、給藥途徑和分銷管道）—全球預測 2025-2032

Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肌萎縮側索硬化症治療市場將成長至 11.8864 億美元，複合年成長率為 7.07%。

主要市場統計數據
基準年2024年 6.8806億美元
預計2025年 7.3306億美元
預測年份：2032年 11.8864億美元
複合年成長率（%） 7.07%

簡要描述 ALS 臨床和商業性前景，以支持策略優先排序和基於證據的專案決策

肌萎縮側索硬化症 (AMSC) 是臨床醫生、研究人員和相關人員面臨的最複雜的神經退化性疾病之一。此疾病的臨床異質性，涵蓋遺傳性和散發性病因，挑戰了傳統的研發模式，並強調了試驗設計、生物標記選擇和治療標靶精準性的重要性。因此，決策者必須整合分子治療、症狀治療和支持性治療等方面的洞見，以建構連貫一致的產品和組合策略。

反義療法、標靶抗氧化劑以及重新調整的對症治療組合的最新進展，正在將臨床討論的重點從單純的支持性治療轉向緩解疾病。同時，監管預期的不斷變化以及對功能效用證據的審查力度的加強，促使申辦方調整研究終點並投資於縱向自然史資料集。因此，商業領導者必須在對症治療產品的短期可及性和報銷途徑與對高成本、更複雜治療方法的長期投資之間取得平衡。

本執行摘要匯集了 ALS 治療整體最重要的趨勢、細分見解、區域趨勢以及針對公司的可行建議，旨在為管理層提供簡明的、基於證據的敘述，以支持在快速發展的治療經營團隊中確定優先次序、降低風險和設計具有商業性可行性的開發計劃。

治療方法創新、不斷演變的證據以及護理服務的變化如何重新定義 ALS 治療的發展和商業化

由於科學進步、監管格局和治療途徑的不斷演變，ALS 治療格局正在發生重大變化。基因標靶療法和反義寡核苷酸已從實驗工具發展成為具有明確轉化潛力的臨床候選藥物，這迫使生物製藥公司重新評估其平台投資和合作策略。同時，幹細胞治療研究正從臨床前模型進展到早期人體研究，其中安全性、給藥途徑和患者選擇是轉化成功的關鍵決定因素。

與治療方法創新同步，真實世界證據生成和數位生物標記正在重塑臨床效用的證明方式。遠端監控技術和客觀功能指標納入試驗方案，透過捕捉疾病軌跡的細微變化，能夠更靈敏地檢測治療訊號。付款人和衛生技術評估機構正在響應這一需求，要求提供將替代性改進與有意義的、以患者為中心的結果聯繫起來的證據，從而影響試驗設計和核准後的證據承諾。

從商業性來看，先進療法的分銷和管理日益複雜，正在重新定義通路策略。鞘內和靜脈注射給藥需要專門的輸液中心和護理協調，這進一步提升了醫院藥房和綜合醫療系統在患者獲取藥物方面的作用。因此，製造商正在建立卓越中心項目，並與臨床網路合作，以簡化交付流程、支持患者依從性並減少物流摩擦。總而言之，這些轉變標誌著病人歷程。

評估 2025 年美國關稅政策變化對神經治療價值鏈的供應鏈、製造和進入影響

貿易和關稅政策的轉變將影響複雜的治療供應鏈，而不僅僅是簡單的成本上漲。美國2025年前不斷變化的關稅格局，對製造策略、採購和價格彈性提出了重要的考量。神經治療中使用的許多原料藥和特殊輔料均在全球範圍內採購，進口關稅的增加可能會加劇投入成本的波動。為此，企業正在重新評估供應商多元化、近岸外包選項和多方採購安排，以保持供應的連續性並降低貿易政策衝擊的風險。

除了原料成本外，關稅還可能影響關鍵生產流程的選址，包括灌裝、低溫運輸物流和專業生技藥品生產。此類營運轉移可能會延長前置作業時間並增加資本密集度，以確保合規的生產佈局。因此，申辦方可能會加快對國內生產能力的投資，或與製造外包簽訂長期協議，以便在確保產能的同時，吸收政策主導的利潤壓力。

重要的是，關稅的累積影響也將波及定價和准入策略。付款人和採購機構可能會密切關注定價趨勢，尤其是高成本專科療法的定價趨勢。在預算緊縮的情況下，製造商可能需要採用更複雜的價值檔案和風險分擔安排，以維持處方藥進入。簡而言之，2025 年的關稅情境強化了主動供應鏈風險管理、靈活採購和綜合商業規劃的必要性，這些規劃需要預測監管機構、經營團隊和付款人對不斷上升的成本壓力的反應。

全面、細分化的分析，將治療方式、患者亞群、給藥途徑和分銷管道與臨床和商業性影響聯繫起來

理解需求和臨床應用需要具備細分觀點，將治療方式與患者亞群、疾病分期、給藥途徑和通路結合。藥物療法包括Dextromethorphan/奎尼丁、Edaravone、Riluzole和托菲森，而治療方法包括基因療法和幹細胞療法。這種基於療法的細分突出表明，小分子對症藥物和神經保護化合物往往遵循既定的門診病人通路，而基因和細胞療法則需要專門的給藥環境和長期安全監測。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對 SOD1 和 C9orf72 基因突變的新型反義寡核苷酸療法用於個人化 ALS 治療
  • 整合穿戴裝置的數位生物標記，即時監測 ALS 患者的活動能力和病情進展
  • Relyvrio（苯丁酸鈉和牛磺樂索二醇）獲得監管部門核准並上市，將改變全球ALS治療方案
  • 幹細胞衍生運動神經元移植技術的進展可望減緩 ALS 的進展
  • 開發包括經顱磁刺激在內的非侵入性神經調節療法來維持 ALS 患者的運動功能
  • 探索粒線體功能調節劑和代謝途徑藥物以解決ALS中的神經元能量缺陷

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 肌萎縮側索硬化症治療市場（依治療方法）

  • 藥物治療
    • Dextromethorphan/奎尼丁
    • Edaravone
    • Riluzole
    • 托弗森
  • 治療方法
    • 基因治療
    • 幹細胞療法

9. 肌萎縮側索硬化症治療市場（按類型）

  • 遺傳性肌萎縮性側索硬化症
  • 散發性 ALS

第 10 章肌萎縮側索硬化症治療市場（依治療階段）

  • 晚期治療
  • 早期治療
  • 中期治療

第 11 章肌萎縮側索硬化症治療市場（依給藥途徑）

  • 椎管內
  • 靜脈
  • 口服

12. 肌萎縮側索硬化症治療市場（按分銷管道）

  • 醫院藥房
  • 零售藥局

第13章肌萎縮側索硬化症治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章肌萎縮側索硬化症治療市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。 肌萎縮側索硬化症治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AB Science SA
    • Alector, Inc.
    • Amylyx Pharmaceuticals, Inc.
    • Apotex Inc.
    • Aquestive Therapeutics, Inc.
    • Ascend Pharmaceuticals LLC
    • AstraEureka Pharmaceuticals
    • Biogen Inc.
    • BrainStorm Cell Limited
    • Cipla Limited
    • CorestemChemon Inc.
    • Coya Therapeutics, Inc.
    • Cytokinetics, Incorporated
    • Dewpoint Therapeutics, Inc.
    • DR. REDDY'S LABORATORIES LIMITED
    • F. Hoffmann-La Roche Ltd
    • Genervon Biopharmaceuticals, LLC
    • GlaxoSmithKline PLC
    • Implicit Bioscience Ltd.
    • Ionis Pharmaceuticals, Inc.
    • ITF Pharma, Inc.
    • Kringle Pharma, Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Neurimmune AG
    • Novartis AG
    • ONO PHARMACEUTICAL CO., LTD.
    • Orion Corporation
    • Orphazyme A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer, Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Treeway BV
    • Viatris Inc.
    • Zydus Lifesciences Limited
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market is projected to grow by USD 1,188.64 million at a CAGR of 7.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 688.06 million
Estimated Year [2025] USD 733.06 million
Forecast Year [2032] USD 1,188.64 million
CAGR (%) 7.07%

Concise contextualization of the ALS clinical and commercial landscape to inform strategic prioritization and evidence-driven program decisions

Amyotrophic lateral sclerosis represents one of the most complex neurodegenerative diseases confronting clinicians, researchers, and commercial stakeholders. The clinical heterogeneity of the condition, spanning familial and sporadic etiologies, challenges conventional development paradigms and elevates the importance of precision in trial design, biomarker selection, and therapeutic targeting. As a result, decision-makers must synthesize insights across molecular therapies, symptomatic agents, and supportive care to frame coherent product and portfolio strategies.

Recent advances in antisense modalities, targeted antioxidants, and repurposed symptomatic combinations have shifted clinical conversations from purely supportive management toward disease-modifying intent. Alongside these clinical developments, shifting regulatory expectations and heightened scrutiny on evidence of functional benefit have prompted sponsors to calibrate endpoints and invest in longitudinal natural history datasets. Consequently, commercial leaders must balance near-term access and reimbursement pathways for symptomatic products with longer-term investment in high-cost, high-complexity modalities.

This executive summary distills the most consequential trends, segmentation insights, regional dynamics, and actionable recommendations for organizations operating across the ALS treatment continuum. The goal is to equip executives with a concise, evidence-driven narrative that supports prioritization, risk mitigation, and the design of commercially viable development programs in a rapidly evolving therapeutic landscape.

How converging therapeutic innovation, evidence evolution, and care delivery transformation are redefining development and commercialization for ALS treatments

The ALS treatment landscape is undergoing transformative shifts driven by converging scientific advances, regulatory nuance, and evolving care pathways. Gene-targeted approaches and antisense oligonucleotides have matured from experimental tools into clinical candidates with clear translational potential, prompting biopharma organizations to re-evaluate platform investments and collaboration strategies. At the same time, stem cell therapy research has progressed from preclinical models to early human studies that emphasize safety, route of administration, and patient selection as critical determinants of translational success.

Parallel to therapeutic innovation, real-world evidence generation and digital biomarkers are reshaping how clinical benefit is demonstrated. Remote monitoring technologies and objective functional metrics are increasingly incorporated into trial protocols to capture granular changes in disease trajectory, enabling more sensitive detection of therapeutic signals. Payers and health technology assessment bodies are responding by seeking evidence that links surrogate improvements to meaningful patient-centric outcomes, thus influencing trial designs and post-approval evidence commitments.

Commercially, the distribution and administration complexities of advanced therapies are redefining channel strategies. Intrathecal and intravenous modalities necessitate specialized infusion centers and care coordination, which elevates the role of hospital pharmacies and integrated health systems in enabling patient access. Consequently, manufacturers are establishing center-of-excellence programs and partnering with clinical networks to streamline delivery, support adherence, and reduce logistical friction. Taken together, these shifts underscore an industry pivot toward integrated development and commercialization approaches that account for the entire patient journey from diagnosis to long-term follow-up.

Assessing the supply chain, manufacturing, and access implications of evolving United States tariff policies for neurological therapeutic value chains in 2025

Policy shifts in trade and tariffs have implications for complex therapeutic supply chains that extend beyond simple cost increments, and the unfolding tariff landscape in the United States for 2025 introduces material considerations for manufacturing strategy, procurement, and pricing resilience. Many active pharmaceutical ingredients and specialty excipients used in neurological therapeutics are sourced globally, and increased import duties can amplify input cost volatility. In response, organizations are reassessing supplier diversification, nearshoring options, and multi-sourcing agreements to preserve continuity of supply and mitigate exposure to trade policy shocks.

Beyond raw material costs, tariffs can influence the location of critical production steps such as fill-finish operations, cold chain logistics, and specialized biologics manufacturing. These operational shifts can extend lead times and increase the capital intensity of ensuring regulatory-compliant manufacturing footprints. Consequently, sponsors may accelerate investments in domestic manufacturing capabilities or long-term contractual commitments with contract manufacturing organizations that can absorb policy-driven margin pressure while guaranteeing capacity.

Importantly, the cumulative impact of tariffs also cascades into pricing and access strategies. Payers and procurement entities are likely to scrutinize price trajectories, particularly for high-cost, specialty therapies. Manufacturers may need to adopt more sophisticated value dossiers and risk-sharing arrangements to maintain formulary access under tightening budget constraints. In short, the tariffs scenario for 2025 reinforces the need for proactive supply chain risk management, flexible sourcing, and integrated commercial planning that anticipates regulatory, operational, and payer responses to increased cost pressures.

A segmentation-focused synthesis that links treatment modalities, patient subgroups, administration routes, and distribution channels to clinical and commercial implications

Understanding demand and clinical adoption requires a segmentation-aware perspective that aligns therapeutic modalities with patient subgroups, stages of disease, routes of administration, and distribution pathways. Based on treatment, the landscape divides into medication and therapies, where medication modalities include dextromethorphan/quinidine, edaravone, riluzole, and tofersen, while therapy approaches span gene therapy and stem cell therapy, each presenting distinct clinical profiles, evidence expectations, and delivery requirements. This treatment-based segmentation highlights that small-molecule symptomatic agents and neuroprotective compounds tend to follow established outpatient distribution channels, whereas gene-based and cellular therapies drive requirements for specialized administration settings and long-term safety surveillance.

Based on type, the dichotomy between familial ALS and sporadic ALS matters considerable for both development strategy and trial enrollment. Familial forms often support targeted molecular approaches with genetically defined mechanisms, enabling more precise patient selection and potentially more rapid proof-of-concept studies. Sporadic ALS, by contrast, demands broader population strategies and biomarker-driven stratification to address etiologic heterogeneity and demonstrate generalizability.

Based on treatment stage, early stage treatment, mid stage treatment, and advanced stage treatment each call for tailored endpoints, supportive care integrations, and risk-benefit considerations. Early stage interventions emphasize slowing progression and preserving function, necessitating sensitive outcome measures and proactive patient identification. Mid stage management focuses on symptom modulation and maintaining quality of life, while advanced stage treatments prioritize palliative integration, respiratory support coordination, and caregiver enablement.

Based on route of administration, intrathecal, intravenous, and oral delivery options shape clinical workflow, monitoring requirements, and adherence considerations. Intrathecal and intravenous routes often require hospital-based administration and specialized training, whereas oral therapies facilitate decentralized care but may encounter challenges with pharmacokinetics and central nervous system penetration. Based on distribution channel, hospital pharmacies and retail pharmacies play complementary roles where hospital pharmacies are central to specialty infusion and intrathecal administration while retail pharmacies support outpatient medication continuity and symptomatic management. Synthesizing these segmentation lenses enables stakeholders to map therapeutic attributes to operational capabilities, payer expectations, and patient access pathways.

Comparative regional dynamics outlining how regulatory, clinical research, and access frameworks across major geographies influence ALS development and commercialization

Regional dynamics materially shape regulatory pathways, clinical trial feasibility, and access frameworks for ALS treatments. In the Americas, regulatory authorities and payer systems exert strong influence on dossier design and reimbursement negotiations, while well-established research networks support rapid patient recruitment for trials that test novel mechanisms. The Americas also host concentrated centers of excellence that enable delivery of specialized intrathecal and intravenous therapies, and integrated health systems play a pivotal role in coordinating multidisciplinary care.

In Europe, Middle East & Africa, stakeholders navigate a mosaic of regulatory frameworks and payer models that require tailored evidence strategies and localized market access planning. Centralized regulatory procedures in some jurisdictions can expedite approvals for certain therapeutics, whereas heterogeneous reimbursement pathways across countries demand flexible pricing and risk-sharing models. Additionally, regional clinical networks and academic consortia are increasingly collaborating on multi-country trials that leverage shared natural history datasets and harmonized endpoints.

Asia-Pacific presents diverse development opportunities and operational considerations; several countries are investing in biotech infrastructure and clinical capacity, which opens pathways for local manufacturing partnerships and regional clinical studies. However, differences in diagnostic practices, genetic epidemiology, and healthcare financing require sponsors to adapt trial protocols and value communication strategies. Across all regions, cross-border collaboration, data sharing, and alignment on real-world evidence standards are becoming essential to support global development programs and ensure equitable patient access to emerging therapeutics.

Competitive and collaborative dynamics that reveal how portfolio strategies, manufacturing partnerships, and patient engagement investments shape ALS therapeutic success

The competitive environment in ALS therapeutics is characterized by a mix of established neurological portfolios, specialist biotech innovators, and contract organizations enabling advanced modality development. Leading pharmaceutical and biotech entities are advancing platform approaches that target molecular drivers of disease, while smaller specialists focus on niche indications, biomarker-driven cohorts, or novel delivery solutions. This diversity generates opportunities for strategic alliances, licensing arrangements, and joint development agreements that align scientific expertise with commercial scale.

Partnerships between developers and specialized contract manufacturers or service providers are increasingly central to managing the complexity of biologic and cellular product manufacturing. These collaborations help translate early-stage proof-of-concept into scalable clinical production while addressing regulatory expectations for quality and traceability. Additionally, payer-facing capabilities and global market access expertise are differentiators for companies seeking broad adoption, prompting acquisitions and collaborations that integrate clinical development with health economics and outcomes research capabilities.

Competition also extends to patient engagement and diagnostic ecosystems; organizations investing in patient registries, remote monitoring platforms, and early diagnostic initiatives can accelerate trial enrollment and strengthen real-world evidence generation. Consequently, companies that combine robust R&D pipelines with deep commercial integration, manufacturing resilience, and patient-centric evidence strategies are best positioned to navigate the complexity of the ALS treatment landscape.

Practical, high-impact strategic measures that align development, supply chain, and access initiatives to de-risk programs and accelerate patient access

Industry leaders must align strategic investments with operational realities to capture therapeutic and commercial opportunities while managing risk. First, prioritize integration between clinical development and payer evidence teams so that trial endpoints, natural history comparators, and health economic models converge early in program design. This alignment reduces downstream access friction and supports robust value communication at launch.

Second, diversify sourcing and manufacturing arrangements to enhance supply chain resilience in the face of trade policy shifts and input scarcity. Near-term tactics include multi-sourcing key intermediates, securing capacity in geographically distributed facilities, and investing in flexible fill-finish capabilities that accommodate modality-specific requirements. Third, invest in partnerships that expand diagnostic reach and patient registry participation to shorten enrollment timelines and improve the representativeness of trial populations, particularly for familial and genetically defined cohorts.

Fourth, design commercialization plans that reflect route-of-administration realities by ensuring hospital systems and specialty pharmacies are engaged early to build treatment pathways and center-of-excellence networks. Fifth, adopt adaptive evidence-generation strategies that combine randomized data with well-structured real-world evidence and digital biomarker endpoints, enabling iterative payer dialogue and post-approval data commitments. Collectively, these actions create a resilient playbook for translating scientific breakthroughs into accessible treatments while managing regulatory, operational, and commercial risk.

A mixed-methods research framework combining primary expert engagement and secondary evidence synthesis with rigorous triangulation to validate therapeutic and operational insights

The research approach underpinning this analysis combined a structured review of peer-reviewed literature, regulatory guidance, and public clinical trial registries with targeted expert interviews across clinical, regulatory, supply chain, and commercial domains. Primary engagement with neurologists, clinical trial investigators, health economists, and supply chain executives provided qualitative validation of emerging modality trends, administration challenges, and payer expectations. Secondary research synthesized scientific publications, regulatory briefing documents, and published treatment guidelines to contextualize therapeutic mechanisms and clinical endpoints.

Data triangulation was used to reconcile differing perspectives and to identify consistent themes regarding evidence needs, delivery constraints, and regional differences. Where possible, methodological rigor was preserved by cross-checking interview insights against documented clinical trial designs and public regulatory decisions. The analysis intentionally emphasized mechanistic and operational factors over proprietary market estimates to ensure the findings remain broadly applicable and decision-focused.

Limitations of the methodology include variability in public disclosure across early-stage programs, heterogeneity in regional regulatory processes, and evolving trade policy contexts that may change after the analysis cut-off. To mitigate these limitations, the study prioritized themes supported by multiple independent sources and sought corroboration from clinical and commercial experts with direct ALS experience.

Summative perspective on the intersecting scientific, operational, and payer considerations that will determine near-term translation of ALS treatment advances into patient access

The ALS therapeutic landscape is at an inflection point where molecular precision, novel delivery modalities, and evolving evidence expectations converge to reshape development and access strategies. Advances in gene-targeted and cellular approaches offer real potential for altering disease trajectory for selected patient cohorts, while improvements in symptomatic agents and monitoring technologies enhance quality-of-life management across disease stages. However, realizing these opportunities requires disciplined alignment of clinical evidence, manufacturing capacity, and payer-focused value demonstration.

Operational risks such as supply chain fragility, tariff-driven cost pressures, and the logistical demands of intrathecal and intravenous administration necessitate proactive mitigation and strategic investment. In parallel, segmentation-aware development that differentiates between familial and sporadic forms, maps stage-specific therapeutic objectives, and matches routes of administration to distribution capabilities will be critical to optimizing trial design and commercial rollout. Ultimately, organizations that couple scientific innovation with purposeful engagement across clinical networks, payers, and delivery partners will be best positioned to translate therapeutic advances into sustainable patient access and long-term impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging antisense oligonucleotide therapies targeting SOD1 and C9orf72 gene mutations for personalized ALS treatment
  • 5.2. Integration of digital biomarkers from wearable devices to monitor ALS patient mobility and disease progression in real time
  • 5.3. Regulatory approvals and market launch of Relyvrio (sodium phenylbutyrate and taurursodiol) transforming global ALS treatment options
  • 5.4. Advances in stem cell-derived motor neuron transplantation techniques showing promise in slowing ALS progression
  • 5.5. Development of non-invasive neuromodulation therapies including transcranial magnetic stimulation to preserve motor function in ALS patients
  • 5.6. Exploration of mitochondrial function modulators and metabolic pathway drugs to address neuronal energy deficits in ALS

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 8.1. Medication
    • 8.1.1. Dextromethorphan/Quinidine
    • 8.1.2. Edaravone
    • 8.1.3. Riluzole
    • 8.1.4. Tofersen
  • 8.2. Therapies
    • 8.2.1. Gene Therapy
    • 8.2.2. Stem Cell Therapy

9. Amyotrophic Lateral Sclerosis Treatment Market, by Type

  • 9.1. Familial ALS
  • 9.2. Sporadic ALS

10. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage

  • 10.1. Advanced Stage Treatment
  • 10.2. Early Stage Treatment
  • 10.3. Mid Stage Treatment

11. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration

  • 11.1. Intrathecal
  • 11.2. Intravenous
  • 11.3. Oral

12. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Amyotrophic Lateral Sclerosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Amyotrophic Lateral Sclerosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Amyotrophic Lateral Sclerosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AB Science SA
    • 16.3.2. Alector, Inc.
    • 16.3.3. Amylyx Pharmaceuticals, Inc.
    • 16.3.4. Apotex Inc.
    • 16.3.5. Aquestive Therapeutics, Inc.
    • 16.3.6. Ascend Pharmaceuticals LLC
    • 16.3.7. AstraEureka Pharmaceuticals
    • 16.3.8. Biogen Inc.
    • 16.3.9. BrainStorm Cell Limited
    • 16.3.10. Cipla Limited
    • 16.3.11. CorestemChemon Inc.
    • 16.3.12. Coya Therapeutics, Inc.
    • 16.3.13. Cytokinetics, Incorporated
    • 16.3.14. Dewpoint Therapeutics, Inc.
    • 16.3.15. DR. REDDY'S LABORATORIES LIMITED
    • 16.3.16. F. Hoffmann-La Roche Ltd
    • 16.3.17. Genervon Biopharmaceuticals, LLC
    • 16.3.18. GlaxoSmithKline PLC
    • 16.3.19. Implicit Bioscience Ltd.
    • 16.3.20. Ionis Pharmaceuticals, Inc.
    • 16.3.21. ITF Pharma, Inc.
    • 16.3.22. Kringle Pharma, Inc.
    • 16.3.23. Mitsubishi Tanabe Pharma Corporation
    • 16.3.24. Neurimmune AG
    • 16.3.25. Novartis AG
    • 16.3.26. ONO PHARMACEUTICAL CO., LTD.
    • 16.3.27. Orion Corporation
    • 16.3.28. Orphazyme A/S
    • 16.3.29. Otsuka Pharmaceutical Co., Ltd.
    • 16.3.30. Pfizer, Inc.
    • 16.3.31. Sanofi SA
    • 16.3.32. Sun Pharmaceutical Industries Ltd
    • 16.3.33. Teva Pharmaceutical Industries Ltd.
    • 16.3.34. Treeway B.V.
    • 16.3.35. Viatris Inc.
    • 16.3.36. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DEXTROMETHORPHAN/QUINIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EDARAVONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RILUZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TOFERSEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY FAMILIAL ALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPORADIC ALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ADVANCED STAGE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY EARLY STAGE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MID STAGE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GCC AMYOTROPHIC LATERAL